Nkarta, Inc. Investing Cash Flow
Nkarta, Inc. (NKTX) reported Investing Cash Flow of $37.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Nkarta, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $21.15M, a 8.50% increase year-over-year.
- Nkarta, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $15.91M, a 70.71% decline year-over-year.
- Nkarta, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $1.10M.
- Nkarta, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $25.39M.
- Nkarta, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $100.32M.
- Nkarta, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$129.56M, a 263.96% decline from fiscal 2023.
- Nkarta, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $79.02M.
- Nkarta, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$184.69M, a 667.68% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $21.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $37.06M 10-Q · filed 2026-08-10 | $38.17M derived: sum of 3 quarters · filed 2026-08-10 | $63.55M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $15.91M 10-Q · filed 2026-05-12 | $17.02M derived: sum of 2 quarters · filed 2026-05-12 | $42.41M derived: sum of 3 quarters · filed 2026-05-12 | $61.90M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $26.49M derived: sum of 2 quarters · filed 2026-03-25 | $45.98M derived: sum of 3 quarters · filed 2026-08-10 | $100.32M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $25.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $44.88M derived: sum of 2 quarters · filed 2026-08-10 | $99.22M 10-Q · filed 2025-11-10 | $94.70M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $19.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $73.83M 10-Q · filed 2026-08-10 | $69.31M derived: sum of 3 quarters · filed 2026-08-10 | $30.41M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $54.34M 10-Q · filed 2026-05-12 | $49.82M derived: sum of 2 quarters · filed 2026-05-12 | $10.92M derived: sum of 3 quarters · filed 2026-05-12 | -$96.70M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$43.41M derived: sum of 2 quarters · filed 2026-03-25 | -$151.04M derived: sum of 3 quarters · filed 2026-03-25 | -$129.56M 10-K · filed 2026-03-25 | |
| 2024-09-30 | -$38.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$146.52M derived: sum of 2 quarters · filed 2025-11-10 | -$125.03M 10-Q · filed 2025-11-10 | -$109.20M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$107.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$86.14M 10-Q · filed 2025-08-12 | -$70.30M derived: sum of 3 quarters · filed 2025-08-12 | -$40.88M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $21.48M 10-Q · filed 2025-05-14 | $37.32M derived: sum of 2 quarters · filed 2025-05-14 | $66.74M derived: sum of 3 quarters · filed 2025-05-14 | $63.57M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $15.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $45.26M derived: sum of 2 quarters · filed 2025-03-26 | $42.09M derived: sum of 3 quarters · filed 2025-03-26 | $79.02M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $29.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $26.25M derived: sum of 2 quarters · filed 2024-11-07 | $63.18M 10-Q · filed 2024-11-07 | $67.92M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $33.76M 10-Q · filed 2024-08-13 | $38.51M derived: sum of 3 quarters · filed 2024-08-13 | -$40.61M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $36.93M 10-Q · filed 2024-05-09 | $41.68M derived: sum of 2 quarters · filed 2024-05-09 | -$37.44M derived: sum of 3 quarters · filed 2024-05-09 | -$146.73M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$74.37M derived: sum of 2 quarters · filed 2024-03-21 | -$183.66M derived: sum of 3 quarters · filed 2024-03-21 | -$184.69M 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$79.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$188.41M derived: sum of 2 quarters · filed 2023-11-09 | -$189.44M 10-Q · filed 2023-11-09 | -$207.27M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$109.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$110.32M 10-Q · filed 2023-08-10 | -$128.16M derived: sum of 3 quarters · filed 2023-08-10 | -$36.64M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$1.03M 10-Q · filed 2023-05-11 | -$18.86M derived: sum of 2 quarters · filed 2023-05-11 | $72.65M derived: sum of 3 quarters · filed 2023-05-11 | $51.70M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$17.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $73.68M derived: sum of 2 quarters · filed 2023-03-16 | $52.73M derived: sum of 3 quarters · filed 2023-03-16 | $32.53M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $91.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $70.56M derived: sum of 2 quarters · filed 2022-11-09 | $50.37M 10-Q · filed 2022-11-09 | -$28.35M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$20.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$41.15M 10-Q · filed 2022-08-11 | -$119.87M derived: sum of 3 quarters · filed 2022-08-11 | -$258.94M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$20.19M 10-Q · filed 2022-05-12 | -$98.92M derived: sum of 2 quarters · filed 2022-05-12 | -$237.99M derived: sum of 3 quarters · filed 2022-05-12 | -$235.17M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$78.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$217.79M derived: sum of 2 quarters · filed 2022-03-17 | -$214.98M derived: sum of 3 quarters · filed 2022-03-17 | -$210.08M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$139.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$136.25M derived: sum of 2 quarters · filed 2021-11-10 | -$131.36M 10-Q · filed 2021-11-10 | -$148.35M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $7.71M 10-Q · filed 2021-08-12 | $7.71M 10-Q · filed 2020-08-20 | -$9.28M derived: sum of 3 quarters · filed 2021-08-12 | -$9.88M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $4.90M 10-Q · filed 2021-05-13 | -$12.09M derived: sum of 2 quarters · filed 2021-05-13 | -$12.69M derived: sum of 3 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$16.99M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$17.59M derived: sum of 2 quarters · filed 2021-03-25 | -$18.30M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$601.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$1.31M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$704.80K 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |